Zacks Small-Cap Research

March 15, 2012
Jason Napodano, CFA
312-265-9421
jnapodano@zacks.com

scr.zacks.com
111 North Canal Street, Chicago, IL 60606

InVivo Therapeutics, Hdls Corp. (NVIV-OTC)

NVIV: Expecting Big Things In 2012…Maintain Outperform Rating.

Current Recommendation	**Outperform**
Prior Recommendation	N/A
Date of Last Change	07/26/2011
Current Price (03/15/12)	$2.40
Target Price	**$4.50**

UPDATE

We are maintaining our 'Outperform' rating and $4.50 price target on shares of InVivo. We remain bullish on the company's long-term prospects with the biopolymer scaffolding device and the injectable hydrogel. Opportunities in spinal cord injury (SCI) and peripheral nerve injury are in the hundred-millions of dollars. In fact, both are blockbuster opportunities given the significant size of the market and the lack of effective treatment options. In our previous reports we have laid out our valuation methodology. We have conducted a discounted cash flow (DCF) analysis and arrive at a target of $4.50. We have also looked at 20 previous deals in the spine market. Applying the average take-out multiple of 6.1x revenues to our 2016 forecast for revenues of $243 million, discounted back to present day at 20%, yields a target price of $7.50 per share.

SUMMARY DATA

52-Week High	**$3.10**
52-Week Low	**$0.60**
One-Year Return (%)	**N/A**
Beta	**0.09**
Average Daily Volume (sh)	**542,243**
Shares Outstanding (mil)	**62**
Market Capitalization ($mil)	**$149**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**2**
Insider Ownership (%)	**35**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2012 Estimate	**N/A**
P/E using 2013 Estimate	**N/A**

Risk Level	**Above Average**
Type of Stock	**Small-Growth**
Industry	**Med-Biomed/Gene**

ZACKS ESTIMATES

Revenue
(In millions of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2011	0 A	0 A	0 A	0 A	0 A
2012	0 E	0 E	0 E	0 E	0 E
2013					1.0 E
2014					1.5 E

Earnings per Share
(EPS is operating earnings before non-recurring items)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2011	-$0.02 A	-$0.03 A	$0.06 E	-$0.70 A	-$0.67 A
2012	-$0.02 E	-$0.06 E	-$0.06 E	-$0.07 E	-$0.21 E
2013					-$0.23 E
2014					-$0.17 E

© Copyright 2012, Zacks Investment Research. All Rights Reserved.

WHAT'S NEW

Financial Position

On March 15, 2012, InVivo Therapeutics reported financial results for the full year 2011. The company reported no revenues in 2011, as expected. For the year ended December 31, 2011, net loss was $34.7 million, or $0.67 per share. Net loss for the year included a non-cash derivative loss of $26.1 million reflecting increases in the fair value of the derivative warrant liability. Excluding this non-cash derivative loss, the pro forma net loss for the year ended December 31, 2011 was $8.7 million, or $0.17 per share.

…Cash Position Solidified…

InVivo exited 2011 with $4.9 million in cash, restricted cash, and short-term investments. During the fourth quarter 2011, InVivo raised approximately $3 million in cash. In December 2011, InVivo entered into a securities purchase agreement with Ingenieria E Inversiones LTDA (IEI-LTDA) whereby the company sold 0.980 million shares of common stock to IEI-LTDA at $2.04 per share, plus issued 0.343 million warrants to purchase additional common stock over the next five years at $3.06 per share. Net proceeds from the transaction were $1.9 million. Also, during the fourth quarter, approximately $1.0 million in warrants were exercised.

In February 2012, InVivo entered into an underwritten public offering of approximately 9.5 million shares at $2.10 per share, to raise net proceeds of $18.1 million. Aegis Capital and Summer Street Research Partners were the underwriting agents for the transaction. We forecast that InVivo will exit the first quarter 2012 with approximately $20.5 million in cash and investments. We find this to be sufficient to fund operations well in 2013.

We remind investors that there were a total of 18.4 million warrants outstanding as of December 31, 2011. This includes 14.9 million warrants currently exercisable at $1.40 per share, and 3.1 million warrants currently exercisable at $1.00 per share, and the 0.3 million noted above exercisable at $3.06 per share. We expect that additional warrants will be exercised over the course of the first and second quarter 2012. In total, all outstanding in-the-money warrants could supply an additional $24 million in cash.

Making Progress Toward The Clinic

…With BSD…

During the second half of 2011, the company took a number of positive steps with respect to bringing its biopolymer scaffold device (BSD) into human clinical trials. InVivo submitted an IDE to the U.S. FDA in July 2011 seeking to commence a human clinical study. InVivo plans to meet with the FDA (CDRH) in April 2012 to finalize the design for the trial. We think talks will center on the inclusion / exclusion criteria.

We are expecting this program to be an open-label design, seeking to enroll a total of 10 patients with endpoints in improvement of function one to two levels below the site of injury. We expect the program will enroll 2 patients (Part-A) and offer initial preliminary data in two months after initiation. If positive, the FDA should allow expansion into the next 8 patients (Part-B). The total time of the trial should be around three to four months. We expect that InVivo will spend the next few months working on scale-up manufacturing for the device. We are expecting the trial to start in the third quarter 2012 and cost around $1.5 million.

If the data is positive, we expect that management will go back to the FDA with a design for a premarket approval (PMA) application. The PMA trial should begin in 2013 and offer data in 2014. Our model assumes a filing for U.S. approval late 2014, with approval in 2015. However, if the IDE data is outstanding, the possibility exists that management can transition to a humanitarian device exemption (HDE) pathway, and qualify for Orphan designation. The HDE pathways greatly speeds the path to market, whereas the Orphan designation will protect from competing products for seven years post launch.

Based on preclinical data from the company's three primate studies, we are optimistic on this IDE program. Previously completed primate data has been published in the Journal of Neuroscience Methods, and won the prestigious 2011 Apple Award from the American Spinal Injury Association recognizing excellence in SCI research.

…With Drug-Releasing Hydrogel…

In the meantime, management is working with the FDA to submit additional data around the company's drug releasing hydrogel for SCI. The company is preparing the rodent and primate data for submission to the agency and seeks to file an IDE around the middle of 2012. We expect the design of the Hydrogel IDE study will be similar to the IDE program for the BSD discussed above. This trial should begin in 2013. If positive, we expect management to expand into a larger PMA program in 2014

Management also seeks to file another IDE around the middle of 2012 for chronic pain due to peripheral nerve damage. Expansion into peripheral nerve damage is a meaningful opportunity for the company. It not only expands the company's focus beyond SCI, but it potentially creates another opportunities to partner or seek non-dilutive funding in 2012.

On January 17, 2012, management announced collaboration with the Geisinger Health System to conduct a preclinical study using the injectable hydrogel for the treatment of chronic pain caused by peripheral nerve compression. The study will be conducted jointly in the Tapinos Lab of Molecular Neuroscience at the Weis Center for Research and the Slotkin Lab of Spinal Cord Injury Research at the Geisinger Clinic's Neurosciences Institute. The endpoint of the study will be the effectiveness of using injectable hydrogels for the controlled release of drugs to alleviate chronic pain resulting from compression-induced peripheral nerve damage looking at both molecular and behavioral impact in rodents. The study is planned to have four arms: 1) injectable scaffold with drug therapy, 2) the injectable scaffold alone, 3) injectable drug therapy alone, and 4) a control group receiving no injection.

We see this as a significant opportunity for InVivo. There are an estimated 3.2 million nerve block injections done in the U.S. each year. It's an estimated $15 billion market. Existing treatment options are limited and only curb pain for as little as one week. A localized injection using the hydrogel to provide time-released anti-inflammatory therapies like methylprednisolone could provide pain relief for up to twelve months with limited systemic side-effects.

New Headquarters In Cambridge

We note that in December 2011, management entered into a multi-year lease for a 21,000 square-foot facility in Cambridge, MA to serve as the company's fully integrated global headquarters. The facility will house InVivo's corporate offices, lab space, a rodent vivarium, and a cGMP cleanroom. Details of the facility include:

- ✓ A chemistry lab for formulations and chemical synthesis of the Company's hydrogel and polymer-based scaffold technologies;
- ✓ A cGMP cleanroom for manufacturing and packaging of the Company's biomaterial devices for clinical studies and early product launch;
- ✓ A rodent vivarium to evaluate the safety and efficacy of various devices and treatment combinations in SCI and other nervous system injury models which the Company believes to be one of the largest dedicated to spinal cord injury research in the world;
- ✓ A biology lab for developing cell therapies used in combination with the Company's biomaterial devices;
- ✓ A surgeon training facility to educate the medical community, prepare for product launch, and engage physicians for research and product development purposes; and,
- ✓ The ability to expand to additional space as the Company grows.

Remaining Bullish On InVivo

We are maintaining our 'Outperform' rating and $4.50 price target on shares of InVivo. We remain bullish on the company's long-term prospects with the biopolymer scaffolding device and the injectable hydrogel. Opportunities in spinal cord injury (SCI) and peripheral nerve injury are in the hundred-millions of dollars. In fact, both are blockbuster opportunities given the significant size of the market and the lack of effective treatment options.

In our previous reports we have laid out our valuation methodology. We have conducted a discounted cash flow (DCF) analysis and arrive at a target of $4.50. We have also looked at 20 previous deals in the spine market. Applying the average take-out multiple of 6.1x revenues to our 2016 forecast for revenues of $243 million, discounted back to present day at 20%, yields a target price of $7.50 per share.

INVESTMENT THESIS

Making The Case For InVivo

In July 2011, we initiated coverage of InVivo Therapeutics with an Outperform rating and $4.50 price target. We are excited about the opportunity that InVivo presents to investors. There are currently no significant treatment options for patients with spinal cord injury (SCI). Although many companies are currently working on pharmaceutical treatment options, we like InVivo's approach with their biopolymer scaffold device (BSD) for several reasons. These include speed to market, simplicity of the idea, intellectual property protection, and strong animal model data.

InVivo is taking a different approach to SCI, focusing on protection of the spinal cord and prevention of secondary injury rather than regeneration. It is often this secondary immune response and inflammation that does the majority of the tissue damage sustained following an acute injury. The company's technology focuses on minimizing tissue damage sustained following acute injury and promoting neural plasticity of the spared healthy tissue, which may result in full or partial functional recovery. In fact, management believes that if as little as 10% of the healthy tissue can be spared, local reorganization can occur that adds meaningfully to functional recovery. We think this is a model that lends itself well to clinical trials. Regulation of BSD will be as a medical device, not a biologic or a pharmaceutical product, which should allow management to move quickly through clinical development. The IDE was filed in July 2011, with human subject trials planned for later in the year.

Longer-term, upside to the story comes from gaining approval for the injectable Hydrogel formulation, which can be used with pharmaceutical products like methylprednisolone sodium succinate (MPSS). This will then be followed by applications for use of BSD in-combination with stem cells. We think this has the potential to turn BSD into a potential blockbuster for the treatment of SCI because it opens up the opportunity to heal stalled SCI wounds in the 250,000 to 300,000 patients in the U.S. currently living with SCI. If we look outside the U.S., and include Canada and Western Europe, and the number grows to 400,000 chronic SCI patients in these markets. Including Asia, Australia, and Latin America, and the number of chronic SCI patients is around 2.0 million worldwide. Beyond SCI, management is looking at the potential to file an IDE into peripheral nerve damage with the injectable Hydrogel. There are an estimated 3 million nerve block procedures done in the U.S. each year. Existing medications work only as long as one week and require frequent follow-ups to maintain pain suppression. InVivo is working on injectable Hydrogel formulations that can block nerve damage pain for up to twelve months.

…Key Attributes…

Although many companies are currently working on pharmaceutical treatment options, we like InVivo's approach with their biopolymer scaffold device (BSD) for several reasons:

- ✓ BSD will be regulated as a medical device. Management filed the Investigational Device Exemption (IDE) to the U.S. FDA in July 2011. The proposed indication is to protect and support spinal tissue and prevent secondary injury, including inflammation and glial scarring, following traumatic spinal cord injury. We think this initial, simpler approach to treating SCI provides investors with a quicker and lower risk path to market than the traditional pharmaceutical or biologic pathway.

- ✓ Strong scientific rationale. InVivo's technology for the BSD was born out of the labs of Robert S. Langer, ScD, Professor at Massachusetts Institute of Technology and Joseph P. Vacanti, MD, affiliated with Massachusetts General Hospital. Dr. Langer has written over 1,100 articles, holds approximately 760 issued and pending patents worldwide that have been licensed or sublicensed to over 220 pharmaceutical, chemical, biotechnology and medical device companies. InVivo's CEO, Frank Reynolds, having suffered a paralyzing injury to his spine in December 1992, has spent years gaining subject matter expertise on the spine and spinal cord.

- ✓ Intellectual property protection is strong. Ultimately, we believe combination therapy will become the standard of care for SCI. InVivo's owns the patent rights to use of all biopolymer scaffolding products which serve as an extracellular matrix for cell therapy, or in in combination with pharmaceutical products or biologic growth factors. These patents also protect the use of time-release drugs, design and manufacture of materials for use in SCI that mimics the natural cellular architecture of the inner grey and outer white matter of the spinal cord. We believe this creates significant barriers to entry for competitors and provides for meaningful licensing and partnering opportunities in the future for InVivo.

- ✓ Animal data has been very encouraging. Although we have only seen data in African Green monkeys, we note the physiological anatomy and neurophysiology characteristics between how the spinal cord works and functions these primates and humans is nearly identical. African Green Monkeys are an acceptable regulatory indicator of potential hazards and research supports translation to humans, Nature Medicine, Vol-13,No.5:561-566, May 2007. The genomic similarity to humans is over 98%. The preclinical data from InVivo has been published in the Journal of Neuroscience Methods, and won the prestigious 2011 Apple Award from the American Spinal Injury Association recognizing excellence in SCI research.

…A Simple Concept…

InVivo is taking a different approach to SCI, focusing on protection of the spinal cord and prevention of secondary injury rather than regeneration. As discussed above, it is often this secondary immune response and inflammation that does the majority of the tissue damage sustained following an acute injury. The company's technology focuses on minimizing tissue damage sustained following acute injury and promoting neural plasticity of the spared healthy tissue, which may result in full or partial functional recovery. In fact, management believes that if as little as 10% of the healthy tissue can be spared, local reorganization can occur that adds meaningfully to functional recovery.



We think this is a model that lends itself well to clinical trials. As noted above, regulation as a Class 3 medical device should allow management to move quickly through clinical development. The IDE was filed in July 2011, with human subject trials planned for the second half of 2012. We could see data from this program by year-end 2012. The next step following this small pilot study remains to be seen. We see two potential next steps following completion of the IDE study:

1. Traditionally, the next step following the IDE is to conduct a larger Pre-Market Approval (PMA) study in approximately 30-40 patients with SCI. Assuming successfully completion of the PMA program, InVivo should be able to file for approval in the U.S. through the 510(k) pathway.

2. With "Homerun" like data from the IDE study, meaning moving patients off a ventilator or taking a complete tetraplegic and returning bowel function or more, InVivo may be able to file for approval in a narrow patient population. An option is to seek approval under the FDA's Humanitarian Device Exemption (HDE) protocol. HDE is similar in both form and content to a Pre-Market Approval (PMA) application, but is exempt from the effectiveness requirements of a PMA. An HDE application is not required to contain the results of scientifically valid clinical investigations demonstrating that the device is effective for its intended purpose. The application, however, must contain sufficient information for FDA to determine that the device does not pose an unreasonable or significant risk of illness or injury, and that the probable benefit to health outweighs the risk of injury or illness from its use. The HDE pathway may allow approval for InVivo's BSD in an acute population or in complete tetraplegics.

Longer-term, upside to the story comes from gaining approval for the injectable Hydrogel formulation, which can be used with pharmaceutical products like methylprednisolone sodium succinate (MPSS). This will then be followed by applications for use of BSD in-combination with stem cells. We think this has the potential to turn BSD into a potential blockbuster for the treatment of SCI because it opens up the opportunity to heal chronic SCI in the 250,000 to 300,000 patients in the U.S. currently living with SCI. If we look outside the U.S., and include Canada and Western Europe, the number grows to 400,000 chronic SCI patients in these markets. Including Asia, Australia, and Latin America, the number of chronic SCI patients is around 2.0 million worldwide.

Beyond SCI, management is looking at the potential to file an IDE into peripheral nerve damage with the injectable Hydrogel. There are an estimated 3 million nerve block procedures done in the U.S. each year. Existing medications work only as long as one week and require frequent follow-ups to maintain pain suppression. InVivo is working on injectable Hydrogel formulations that can block nerve damage pain for up to twelve months.

PROJECTED FINANCIALS

InVivo Therapeutics Holdings Corp.
Income Statement

InVivo Therapeutics	2010 E	2011 A	Q1 E	Q2 E	Q3 E	Q4 E	2012 E	2013 E	2014 E	2015 E
Product Sales	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$93.7**
YOY Growth	-	-	-	-	-	-	-	-	-	-
Collaborative & Licensing	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$1.0**	**$1.5**	**$1.5**
YOY Growth	-	-	-	-	-	-	-	-	-	-
Total Revenues	**$0**	**$0**	**$0**	**$0.0**	**$0.0**	**$0.0**	**$0.0**	**$1.0**	**$1.5**	**$95.2**
YOY Growth	-	-	-	-	-	-	-	-	-	-
Cost of Goods / Services	$0	$0	$0	$0	$0	$0	$0	$0	$0.0	$9.4
Product Gross Margin	-	-	-	-	-	-	-	-	-	-
R&D	$1.7	$4.1	$1.1	$1.1	$1.4	$1.7	$5.3	$10.0	$10.0	$10.0
% R&D	-	-	-	-	-	-	-	-	-	-
SG&A	$1.7	$4.6	$1.4	$1.5	$1.5	$1.6	$6.0	$7.0	$8.0	$20.7
% SG&A	-	-	-	-	-	-	-	-	-	-
Operating Income	($3.4)	($8.7)	($2.5)	($2.6)	($2.9)	($3.3)	($11.3)	($16.0)	($16.5)	$55.1
Operating Margin	*0.0%*	-	-	-	-	-	-	-	-	-
Net Other Income	($4.5)	($26.1)	$1.5	($1.0)	($1.0)	($1.0)	($1.5)	$0.0	$0.0	$0.0
Pre-Tax Income	($7.9)	($34.8)	($1.0)	($3.6)	($3.9)	($4.3)	($12.8)	($16.0)	($16.5)	$55.1
Taxes	$0	$0	$0	$0	$0	$0	$0	$0	$3.9	$15.8
Tax Rate	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*23.5%*	*28.6%*
Net Income	($7.9)	($34.8)	($1.0)	($3.6)	($3.9)	($4.3)	($12.8)	($16.0)	($12.6)	$39.3
Net Margin	*0.0%*	-	-	-	-	-	-	-	*-841.3%*	*41.3%*
Reported EPS	**($0.24)**	**($0.67)**	**($0.02)**	**($0.06)**	**($0.06)**	**($0.07)**	**($0.21)**	**($0.23)**	**($0.17)**	**$0.49**
YOY Growth	-	-	-	-	-	-	-	-	-	-
Wt. Ave Shares Outstanding	33.4	51.9	58.0	62.5	62.5	62.5	61.4	70.0	75.0	80.0

Source: Zacks Investment Research, Inc. *Jason Napodano, CFA*

© Copyright 2012, Zacks Investment Research. All Rights Reserved.

HISTORICAL ZACKS RECOMMENDATIONS



DISCLOSURES

The following disclosures relate to relationships between Zacks Investment Research ("ZIR") and Zacks Small-Cap Research ("Zacks SCR") and the issuers covered by the Zacks SCR analysts in the Small-Cap Universe.

ZIR or Zacks SCR Analysts do not hold or trade securities in the issuers which they cover. Each analyst has full discretion on the rating and price target based on their own due diligence. Analysts are paid in part based on the overall profitability of Zacks SCR. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by Zacks SCR for non-investment banking services. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or blog.

ZIR and Zacks SCR do not make a market in any security nor do they act as dealers in securities. Zacks SCR has never received compensation for investment banking services on the small-cap universe. Zacks SCR does not expect received compensation for investment banking services on the small-cap universe. Zacks SCR has received compensation for non-investment banking services on the small-cap universe, and expects to receive additional compensation for non-investment banking services on the small-cap universe, paid by issuers of securities covered by Zacks SCR. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, investment research, and investment management.

Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Because of individual objectives, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change. Reports are not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. Zacks SCR uses the following rating system for the securities it covers. Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters. Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters. Sell/Underperform: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters.

The current distribution of Zacks Ratings is as follows on the 1026 companies covered: Buy/Outperform- 16.3%, Hold/Neutral- 77.1%, Sell/Underperform – 5.8%. Data is as of midnight on the business day immediately prior to this publication.

© Copyright 2012, Zacks Investment Research. All Rights Reserved.